Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,600
Employees17,600
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,600
Employees17,600

GILD Key Statistics

Market cap
136.38B
Market cap136.38B
Price-Earnings ratio
24.08
Price-Earnings ratio24.08
Dividend yield
2.72%
Dividend yield2.72%
Average volume
7.29M
Average volume7.29M
High today
$114.42
High today$114.42
Low today
$109.32
Low today$109.32
Open price
$113.67
Open price$113.67
Volume
6.12M
Volume6.12M
52 Week high
$119.96
52 Week high$119.96
52 Week low
$69.91
52 Week low$69.91

GILD News

TipRanks 12h
Gilead estimates Q2 acquired IPR&D expenses of $61M

For the second quarter of 2025, Gilead (GILD) currently expects $61M in acquired IPR&D expenses, representing a charge of roughly 4c to both GAAP and non-GAAP e...

TipRanks 2d
Gilead Sciences’ New HIV Treatment Study: A Potential Game Changer?

Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advan...

Simply Wall St 3d
Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug

recently announced a partnership with the Global Fund to supply lenacapavir for HIV prevention, marking a significant client collaboration. This and other posit...

Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug

Analyst ratings

60%

of 30 ratings
Buy
60%
Hold
40%
Sell
0%

More GILD News

Benzinga 3d
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenac...

Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
Benzinga 3d
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'

In a rapidly evolving financial landscape, insights from top investment strategists and analysts can significantly influence market sentiment and investment str...

Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.
VeriSign
Vertex Pharmaceuticals
Exelixis
Spotify
United Therapeutics
Sprouts Farmers Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.